Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Drops By 48.1%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 562,363 shares, a drop of 48.1% from the April 30th total of 1,083,465 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 643,391 shares, the short-interest ratio is currently 0.9 days.

Liminatus Pharma Stock Performance

Shares of Liminatus Pharma stock traded up $0.02 on Monday, hitting $0.18. The company’s stock had a trading volume of 6,452,543 shares, compared to its average volume of 10,947,683. Liminatus Pharma has a 1 year low of $0.13 and a 1 year high of $33.66. The firm has a fifty day moving average price of $0.19 and a 200-day moving average price of $0.53. The company has a market capitalization of $8.17 million and a price-to-earnings ratio of -0.42.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.03) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Liminatus Pharma currently has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.